Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Albert DavidNSE:ALBERTDAVD +3.34%75 EBITDA Margin % is 38.09% as of Jun. 2026, which is 221% above its 10-year median of 11.86. GuruFocus rates NSE:ALBERTDAVD with a GF Score™ of 75/100 and a GF Value™ of ₹904.43 (Fairly Valued). The stock has 7 warning signs investors should review. Among 957 Drug Manufacturers companies, Albert David ranks worse than 68.76% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Albert David's EBITDA for the
three
months ended in Jun. 2026 was ₹386 Mil. Albert David's Revenue for the
three
months ended in Jun. 2026 was ₹1,013 Mil. Therefore, Albert David's EBITDA margin for the quarter that ended in Jun. 2026 was 38.09%.
Albert David (NSE:ALBERTDAVD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Albert David EBITDA Margin % Related Terms
Albert David EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Albert David's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Albert David's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Albert David EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Albert David's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Albert David's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Albert David (NSE:ALBERTDAVD) has a EBITDA Margin % of 38.09% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Albert David and its competitors. This is 221% above median its historical median of 11.86. Over the past decade, Albert David's EBITDA Margin % has ranged from 3.90 to 28.96. According to the industry distribution chart, Albert David ranks #658 out of 957 companies in the Drug Manufacturers industry, placing it in the top 68.8%.
Is Albert David's EBITDA Margin % too high?
Albert David's current EBITDA Margin % of 38.09% is 221% above median its 10-year median of 11.86. Over the past 10 years, this metric has ranged from a low of 3.90 to a high of 28.96. The Drug Manufacturers industry median EBITDA Margin % is 12.01. Albert David's value of 38.09% is 217.2% above this industry median. Based on the distribution chart, Albert David ranks #658 out of 957 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Albert David has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Albert David's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Albert David ranks #658 out of 957 companies for EBITDA Margin %. This places Albert David in the lower half of its industry. The industry median EBITDA Margin % is 12.01. Albert David's value of 38.09% is 217.2% above this benchmark. Historically, Albert David's own EBITDA Margin % has ranged from 3.90 to 28.96 over the past decade. While the company's 10-year median is 11.86 vs. the industry median of 12.01, Albert David has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.01, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Albert David's current EBITDA Margin % of 38.09% is 217.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Albert David and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Albert David's current EBITDA Margin % is 38.09%, which is 221% above median its own 10-year median of 11.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Albert David stock overvalued right now?
Based on GuruFocus' analysis, Albert David (NSE:ALBERTDAVD) is currently considered Fairly Valued. The stock's GF Value™ is ₹904.43, compared to a current price of ₹833.05 — trading 7.9% below its estimated fair value. The current EBITDA Margin % is 38.09%, which is 221% above median its 10-year median of 11.86 and 217.2% above the Drug Manufacturers industry median of 12.01. Albert David's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Albert David (NSE:ALBERTDAVD), the current EBITDA Margin % is 38.09% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Albert David (NSE:ALBERTDAVD) Overvalued in 2026?
Based on GuruFocus' analysis, Albert David stock appears to be undervalued.
The current stock price of ₹833.05 is trading 7.9% below its estimated GF Value™ of ₹904.43.
GuruFocus considers Albert David to be Fairly Valued.
Key valuation signals for NSE:ALBERTDAVD:
EBITDA Margin %: 38.09% (221% above median its 10-year median of 11.86)
GF Value™: ₹904.43 vs. price of ₹833.05 (7.9% below fair value)
Industry Position: 217.2% above the Drug Manufacturers median (#658 of 957)
No single metric tells the full story. See the NSE:ALBERTDAVD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Albert David Ltd is engaged in the manufacturing and trading of pharmaceutical products. The company offers products such as pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs. Its formulation product covers parenteral, oral, enteral, topical agents, and vision care solutions. The company exports its product to regions like Latin America, Southeast Asia, and a few African countries. The Company is only engaged in the manufacturing of pharmaceutical products, ipso facto, one reportable segment.
75GF Score
Get the complete analysis for NSE:ALBERTDAVD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALBERTDAVD has been successfully added to your 
